Novo Nordisk (NOV) Financial Statements
Novo Nordisk Financial Overview
Novo Nordisk's market cap is currently $145.10B. The company's EPS TTM is $26.22; its P/E ratio is 10.15; and it has a dividend yield of 3.97%. Novo Nordisk is estimated to report earnings on November 4, 2026, and the estimated EPS forecast is $0.58. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 309.06B | $ 290.40B | $ 232.26B | $ 176.95B | $ 140.80B |
| Gross Profit | $ 250.28B | $ 245.88B | $ 196.50B | $ 148.51B | $ 117.14B |
| Operating Income | $ 127.66B | $ 128.34B | $ 102.57B | $ 74.81B | $ 58.64B |
| EBITDA | $ 149.41B | $ 137.38B | $ 114.63B | $ 76.80B | $ 65.39B |
| Net Income | $ 102.43B | $ 100.99B | $ 83.68B | $ 55.52B | $ 47.76B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 26.96B | $ 26.31B | $ 30.23B | $ 23.57B | $ 17.48B |
| Total Assets | $ 542.90B | $ 465.80B | $ 314.49B | $ 241.26B | $ 194.51B |
| Total Debt | $ 130.96B | $ 102.79B | $ 27.01B | $ 25.78B | $ 26.64B |
| Net Debt | $ 104.49B | $ 87.13B | $ 12.61B | $ 13.13B | $ 15.93B |
| Total Liabilities | $ 348.86B | $ 322.31B | $ 207.93B | $ 157.77B | $ 123.76B |
| Stockholders' Equity | $ 194.05B | $ 143.49B | $ 106.56B | $ 83.49B | $ 70.75B |
| Cash Flow | |||||
| Free Cash Flow | $ 28.99B | $ 69.66B | $ 70.01B | $ 64.13B | $ 47.62B |
| Operating Cash Flow | $ 119.10B | $ 120.97B | $ 108.91B | $ 78.89B | $ 55.00B |
| Investing Cash Flow | $ -79.16B | $ -128.90B | $ -43.89B | $ -24.92B | $ -31.61B |
| Financing Cash Flow | $ -28.41B | $ 8.73B | $ -63.16B | $ -51.80B | $ -25.49B |
Currency in DKK